BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis
Shots:
- Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program- including the lead investigational asset- AVID200. The transaction is expected to be closed in Q4’20
- Prior to closing- Forbius’ non-TGF-beta assets will be transferred to a newly formed private company- which will be retained by Forbius’ existing shareholders
- AVID200 is a highly potent and isoform-selective TGF-beta inhibitor that neutralizes TGF-beta 1 and -beta 3 with picomolar potency- currently being evaluated in P-I study for Oncology and Fibrosis
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
